{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:36:30Z","timestamp":1793108190006,"version":"4.5.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>An increasing number of acute myeloid leukemia (AML) therapeutics have been developed, not as cytotoxic therapies but rather as targeted agents able to restore the aberrant and leukemogenic \u201cblock\u201d in normal differentiation. All-trans retinoic acid and arsenic trioxide are classic examples of differentiating agents for treatment of acute promyelocytic leukemia (APL); newer therapies functioning through differentiation include isocitrate dehydrogenase 1 and 2 inhibitors, FMS-like tyrosine kinase 3 inhibitors, and menin inhibitors. The terminal differentiation of leukemic blasts via differentiating-agent therapy can lead to a constellation of signs and symptoms, originally referred to as \u201cretinoic acid syndrome\u201d and now termed \u201cdifferentiation syndrome\u201d (DS), characterized predominantly by systemic inflammatory response system\u2013like features of dyspnea, pulmonary infiltrates, pleural and pericardial effusions, unexplained fevers, hypotension, edema, and renal insufficiency. DS in patients with newly diagnosed APL is generally straightforward to identify; however, DS in patients with multiply relapsed AML can be more challenging to diagnose, due to nonspecific signs and symptoms that can be mistakenly attributed to infectious etiologies or the underlying refractory leukemia itself. Prompt consideration of DS, rapid initiation of systemic corticosteroids, and early cytoreduction in the setting of concomitant hyperleukocytosis are essential for optimal management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024024008","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T16:55:26Z","timestamp":1720457726000},"page":"1251-1259","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["How I treat acute myeloid leukemia with differentiation therapy"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"2Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2025032015213293500_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025032015213293500_bib2","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2025032015213293500_bib3","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2025032015213293500_bib4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025032015213293500_bib5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2025032015213293500_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"10388","key":"2025032015213293500_bib7","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"22","key":"2025032015213293500_bib8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2025032015213293500_bib9","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2025032015213293500_bib11","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \"retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med"},{"issue":"2","key":"2025032015213293500_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2025032015213293500_bib14","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome","volume":"95","author":"Tallman","year":"2000","journal-title":"Blood"},{"issue":"9","key":"2025032015213293500_bib15","first-page":"3015","article-title":"A\u00a0modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML\/RARalpha-positive acute promyelocytic leukemia. PETHEMA group","volume":"94","author":"Sanz","year":"1999","journal-title":"Blood"},{"issue":"19","key":"2025032015213293500_bib16","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1182\/blood-2010-02-269621","article-title":"Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710","volume":"116","author":"Powell","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"issue":"25","key":"2025032015213293500_bib18","doi-asserted-by":"crossref","first-page":"5137","DOI":"10.1182\/blood-2010-01-266007","article-title":"Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome","volume":"115","author":"Sanz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2025032015213293500_bib19","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/blood-2012-08-449918","article-title":"Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL","volume":"121","author":"Rego","year":"2013","journal-title":"Blood"},{"issue":"36","key":"2025032015213293500_bib20","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1200\/JCO.2006.08.1596","article-title":"Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group","volume":"24","author":"Ad\u00e8s","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2025032015213293500_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2012-02-410746","article-title":"All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)","volume":"120","author":"Iland","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib22","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"2025032015213293500_bib23","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1182\/blood-2018-03-836528","article-title":"Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL","volume":"132","author":"Testi","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025032015213293500_bib25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of arsenic trioxide and all-trans retinoic acid for the treatment of pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group AAML1331 Trial","volume":"8","author":"Kutny","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"2025032015213293500_bib26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08325.x","article-title":"Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia","volume":"151","author":"Luesink","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"2025032015213293500_bib27","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1182\/blood.V83.11.3264.3264","article-title":"Hematopoietic growth factor expression and ATRA sensitivity in acute promyelocytic blast cells","volume":"83","author":"Dubois","year":"1994","journal-title":"Blood"},{"issue":"1","key":"2025032015213293500_bib28","first-page":"95","article-title":"All-trans retinoic acid rapidly decreases cathepsin G synthesis and mRNA expression in acute promyelocytic leukemia","volume":"10","author":"Seale","year":"1996","journal-title":"Leukemia"},{"issue":"27","key":"2025032015213293500_bib29","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"issue":"27","key":"2025032015213293500_bib30","doi-asserted-by":"crossref","first-page":"13863","DOI":"10.1016\/S0021-9258(18)68323-1","article-title":"Transcriptional regulation of the leukocyte adherence protein beta subunit during human myeloid cell differentiation","volume":"263","author":"Hickstein","year":"1988","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2025032015213293500_bib31","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.V90.7.2747","article-title":"Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2","volume":"90","author":"Larson","year":"1997","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib32","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1164\/ajrccm.158.4.9709085","article-title":"Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome","volume":"158","author":"Nicolls","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"2025032015213293500_bib33","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"de Botton","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025032015213293500_bib34","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025032015213293500_bib35","unstructured":"Idhifa (enasidenib) [prescribing information]. Bristol Myers Squibb. Accessed 7 June 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209606s000lbl.pdf."},{"key":"2025032015213293500_bib36","unstructured":"Tibsovo (ivosidenib) [prescribing information]. Servier Laboratories. Accessed 7 June 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/211192_s008lbl.pdf."},{"key":"2025032015213293500_bib37","unstructured":"Rezildhia (olutasidenib) [prescribing information]. San\u00a0Francisco, CA: Rigel Pharmaceuticals, Inc. Accessed 7 June 2024. https:\/\/www.rezlidhia.com\/."},{"issue":"16","key":"2025032015213293500_bib38","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025032015213293500_bib39","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"2025032015213293500_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2013-01-478172","article-title":"FLT3 inhibitor-induced neutrophilic dermatosis","volume":"122","author":"Fathi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2025032015213293500_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamadermatol.2015.6121","article-title":"FLT3 inhibitor-associated neutrophilic dermatoses","volume":"152","author":"Varadarajan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025032015213293500_bib42","unstructured":"Xospata (gilteritinib) [prescribing information]. Northbrook, IL: Astellas Pharma, Inc. Accessed 7 June 2024. https:\/\/astellas.us\/docs\/xospata.pdf."},{"key":"2025032015213293500_bib43","unstructured":"Vanflyta (quizartinib) [prescribing information]. Daiichi Sankyo. Accessed 7 June 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216993s000lbl.pdf."},{"issue":"10","key":"2025032015213293500_bib44","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2025032015213293500_bib45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2015.320","article-title":"Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone","volume":"30","author":"Nybakken","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"2025032015213293500_bib46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"issue":"3","key":"2025032015213293500_bib47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"issue":"10","key":"2025032015213293500_bib48","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"issue":"7954","key":"2025032015213293500_bib49","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"issue":"suppl 2","key":"2025032015213293500_bib50","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood-2023-192042","article-title":"Revumenib monotherapy in patients with relapsed\/refractory KMT2Ar acute leukemia: topline efficacy and safety results from the pivotal augment-101 phase 2 study [abstract]","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"key":"2025032015213293500_bib51","doi-asserted-by":"crossref","first-page":"S304","DOI":"10.1016\/S2152-2650(23)01067-4","article-title":"AML-475 activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed\/refractory NPM1-mutated AML","volume":"23","author":"Erba","year":"2023","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"suppl\u00a01","key":"2025032015213293500_bib52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A\u00a0first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed\/refractory acute leukemia harboring KMT2A or NPM1 alterations [abstract]","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2025032015213293500_bib53","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2023-178090","article-title":"Preliminary results from a phase 1 dose escalation study of FHD-286, a novel BRG1\/BRM (SMARCA4\/SMARCA2) inhibitor, administered as an oral monotherapy in patients with advanced hematologic malignancies [abstract]","volume":"142","author":"DiNardo","year":"2023","journal-title":"Blood"},{"issue":"36","key":"2025032015213293500_bib54","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-human phase I study of iadademstat (ORY-1001): a first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032015213293500_bib55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.12598","article-title":"Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine","volume":"95","author":"Laufer","year":"2015","journal-title":"Eur J Haematol"},{"issue":"16","key":"2025032015213293500_bib56","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2025032015213293500_bib57","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.3390\/cancers15194767","article-title":"Differentiation syndrome in acute leukemia: APL and beyond","volume":"15","author":"Woods","year":"2023","journal-title":"Cancers"},{"issue":"13","key":"2025032015213293500_bib58","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025032015213293500_bib59","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-021-00514-3","article-title":"Acute promyelocytic leukemia current treatment algorithms","volume":"11","author":"Yilmaz","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2025032015213293500_bib60","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024024008\/2359140\/blood_bld-2024-024008-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2024024008\/2359140\/blood_bld-2024-024008-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T17:44:55Z","timestamp":1742492695000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/12\/1251\/516867\/How-I-treat-acute-myeloid-leukemia-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":60,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,3,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024008","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}